A comparison of biological therapies vs traditional immunosuppressant in the management of Inflammatory bowel diseases: A Narrative Review

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic immune-mediated condition requiring long-term management. Traditional immunosuppressants, such as corticosteroids, thiopurines, and methotrexate, have been widely used but are associated with broad immunosuppressive effects and significant adverse events. The advent of biological therapies, including tumor necrosis factor (TNF) inhibitors, integrin inhibitors, and interleukin (IL)-12/23 inhibitors, has revolutionized IBD treatment by offering targeted immune modulation. Biologics have demonstrated superior efficacy in achieving and maintaining remission compared to traditional immunosuppressants, particularly in moderate to severe IBD. They provide targeted immune suppression, reducing systemic side effects, but are associated with risks such as infections, immunogenicity, and high costs. Traditional immunosuppressants remain relevant for milder cases and as combination therapy but are limited by delayed onset of action and toxicity concerns. Despite these advances, challenges such as treatment accessibility, high costs, and loss of response persist. The introduction of biosimilars and novel small-molecule drugs may improve treatment affordability, while personalized medicine approaches, including biomarker-driven therapy selection and therapeutic drug monitoring, are emerging as crucial strategies to optimize treatment outcomes. While biological therapies have transformed IBD management, future research should focus on refining treatment strategies, improving long-term safety, and enhancing accessibility to ensure better patient outcomes.